Efficacy and Safety of 5–Grass-Pollen Sublingual Immunotherapy Tablets in Pediatric Allergic Rhinoconjunctivitis

STUDY POPULATION. Subjects were 278 children (age: 5–14 years) with seasonal grass pollen-induced allergic rhinoconjunctivitis for 2 years. Allergy was confirmed by a timothy grass-specific immunoglobulin E (IgE) level of at least class 2 and a wheal diameter of 3 mm in a skin-prick test containing 5 grass pollens included in the SLIT tablet (orchard, meadow, perennial rye, sweet vernal, and timothy grasses). Patients who were sensitized to other allergens present during the grass pollen season, patients who had previously received immunotherapy for grass pollen allergy, and patients with asthma who were receiving medications other than 2-adrenergic receptor agonists were excluded.